Dave N T Aryee Selected Research

EWS-FLI fusion protein

1/2021	YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells.
7/2018	Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers.
4/2017	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
2/2017	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma.
1/2016	EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway.
11/2014	Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.
1/2011	Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.
5/2010	Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.
9/2008	EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma.
10/2006	Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dave N T Aryee Research Topics

Disease

15	Ewing Sarcoma (Sarcoma, Ewing) 01/2021 - 08/2002
11	Neoplasms (Cancer) 01/2022 - 08/2002
5	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2010
3	Genetic Translocation (Chromosomal Translocation) 04/2017 - 10/2006
2	Bone Neoplasms (Bone Cancer) 01/2021 - 07/2018
1	Genomic Instability 04/2017
1	Hypoxia (Hypoxemia) 05/2010
1	Carcinogenesis 09/2008
1	Breast Neoplasms (Breast Cancer) 08/2002
1	Neuroblastoma 08/2002

Drug/Important Bio-Agent (IBA)

13	EWS-FLI fusion proteinIBA 01/2021 - 08/2002
6	Proteins (Proteins, Gene)FDA Link 01/2016 - 08/2002
3	Proto-Oncogene Proteins c-etsIBA 04/2017 - 08/2002
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 02/2017
2	Transcription Factors (Transcription Factor)IBA 10/2006 - 04/2005
1	Untranslated RNA (Noncoding RNA)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Verteporfin (Visudyne)FDA Link 01/2021
1	NAD (NADH)IBA 04/2017
1	Adenine FDA LinkGeneric 04/2017
1	MicroRNAs (MicroRNA)IBA 02/2017
1	Notch ReceptorsIBA 11/2014
1	Sirtuin 1IBA 11/2014
1	tenovin-6IBA 11/2014
1	Chemokine ReceptorsIBA 07/2010
1	AgarIBA 05/2010
1	Single-Chain AntibodiesIBA 10/2006
1	ChromatinIBA 04/2005
1	DNA (Deoxyribonucleic Acid)IBA 08/2002
1	Messenger RNA (mRNA)IBA 08/2002

Therapy/Procedure

2	Therapeutics 10/2021 - 07/2018
1	Immunotherapy 10/2021
1	Surgical Instruments (Clip) 02/2017